Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:


The results of large-scale clinical trials have convincingly demonstrated the effectiveness of acetylsalicylic acid (ASA) in primary and secondary prevention of atherothrombotic events. Studies on the safety of different ASA formulations have been continuing. Magnesium hydroxide included in combined medicine, Сardiomagnil, prevents ASA adverse effects on the gastric mucosa and reduces in severity of dyspeptic symptoms.

About the Authors

A. V. Govorin
Chita State Medical Academy
Russian Federation

A. P. Filev
Chita State Medical Academy
Russian Federation


1. Kosarev V .V ., Babanov S.A., Verbovoy A.F . Handbook of clinical pharmacology . Rostov-na-Donu: Feniks; 2011. Russian (Косарев В.В., Бабанов С.А., Вербовой А.Ф. Справочник клинического фармаколога. Ростов-на-Дону: Феникс; 2011).

2. Lepakhin V.K., editor . Pharmacology and drug therapy. Moscow: Eksmo; 2009. Russian (Лепахин В.К., редактор. Фармакология и лекарственная терапия. М.: Эксмо; 2009).

3. Shal'nova S.A., Deev A.D., Oganov R.G. Factors influencing the mortality from cardiovascular diseases in the Russian population. Kardiovaskulyarnaya Terapiya i Profilaktika 2005; (1): 4–9. Russian (Шальнова С.А., Деев А.Д., Оганов Р .Г . Факторы, влияющие на смертность от сердечно-сосудистых заболеваний в российской популяции. Кардиоваскулярная Терапия и Профилактика 2005; (1): 4–9).

4. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988; 2(8607): 349–60.

5. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71–86.

6. Antithrombotic Trialists (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373 (9678): 1849–60.

7. Lewis HD Jr , Davis JW, Archibald DG et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med 1983; 309 (7): 396–403.

8. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 336: 827–30.

9. Collaborative overview of randomised trials of antiplatelet therapy-II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. BMJ 1994; 308: 159–68.

10. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation 2008; 117 (2): 261–95.

11. Ridker Р .М., Manson J.E., Gaziano J.M. et al. Low-dose aspirin therapy for chronic stable angina. A randomized, placebo-controlled clinical trial. Ann Intern Med 1991; 114 (10): 835–9.

12. Juul-Muller S., Edvardsson N., Jahnmatz B. et al. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet 1992; 340 (8833): 1421–5.

13. Final report on the aspirin component of the ongoing Physicians’ Health Study. Steering Commitee of the Physicians’ Health Study Research Group. N Engl J Med 1989; 321: 129–35.

14. Peto R., Gray R., Collins R. et al. Randomized trial of prophylactic daily aspirin in British male doctors. BMJ 1988; 296: 313–316.

15. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council’s General Practice Research Framework. Lancet 1998; 351: 233–241.

16. Hansson L., Zanchetti A., Carruthers S.G. et al. Effects of intensive blood-pressure lowering and low dose aspirin in patients with hypertension: principal results of Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1988; 351: 1762–66.

17. Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 2001; 357: 89–95.

18. Ridker P ., Cook N., Min Lee L. et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352 (13): 1293–304.

19. Montgomery PR, Berger LG, Mitenko PA, Sitar DS. Salicylate metabolism: effects of age and sex in adults. Clin Pharmacol Ther 1986; 39: 571.

20. Ridker P .M., Cook N.R., Lee I.M. et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352 (13): 1293–304.

21. Lichtenstein D., Syngal S., Wolfe M. Nonsteroidal antiinflammatory drugs and the gastrointestinal tract. The double-edged sword. Arthritis Rheum 1995; 38 (1): 5–18.

22. Karateev A.E., Nasonov E.L., Koreshkov G.G. NSAID-induced dyspepsia: prevalence and possible medical treatment. Nauchno-Prakticheskaya Revmatologiya 2003; (5): 76–78. Russian (Каратеев А.Е., Насонов Е.Л., Корешков Г .Г . НПВП-индуцированная диспепсия: распространенность и возможность медикаментозной коррекции. Научно-Практическая Ревматология 2003; (5): 76–78).

23. Awtry E.H. Loscalzo J. Aspirin. Circulation 2000; 101: 1206–18.

24. Patrono C, Coller B, FitzGerald GA et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (S suppl): 234S–264S.

25. Jaszewski R. Frequency of gastroduodenal lesions in asymptomatic patients on chronic aspirin or nonsteroidal antiinflammatory drug therapy. J Clin Gastroenterol 1990; 12: 10–13.

26. Latini R., Cerletti C., de Gaetano G. et al. Comparative bioavailability of aspirin from buffered, enteric-coated and plain preparations. Int J Clin Pharmacol Ther Toxicol 1986; 24: 313–318.

27. Hawthorne A.B., Mahida Y .R., Cole A.T ., Hawkey C.J. Aspirin-induced gastric mucosal damage: prevention by enteric-coating and relation to prostaglandin synthesis. Br J Clin Pharmacol 1991; 32: 77–83.

28. Gantt AJ, Gantt S. Comparison of enteric-coated aspirin and uncoated aspirin effect on bleeding time. Cathet Cardiovasc Diagn 1998;45(4):396–9.

29. Roderick P .J., Wilkes H.C., Meade T .W. The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials. Br J Clin Pharmacol 1993; 35: 219–226.

30. Kelly J.P ., Kaufman D.W., Jurgelon J.M. et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996; 348: 1413–1416.

31. Slattery D.E., Pollack C.V. Balancing Potency of Platelet Inhibition with Bleeding Risk in the Early Treatment of Acute Coronary Syndrome. West J Emerg Med 2009; 10(3): 163–175.

32. Ivashkin V.T . Place of antacids in the modern treatment of peptic ulcer . Russkiy Meditsinskiy Zhurnal 2002; 4(2) suppl: 42–46. Russian (Ивашкин В.Т . Место антацидов в современной терапии язвенной болезни. Русский Медицинский Журнал 2002; 4(2) Приложение: 42–46).

33. Schmidt C., Baumeister B., Kipnowski J. and oth. Magaldrate stimulates endogenous prostaglandin E2 synthesis in human gastric mucosa in vitro and in vivo. Hepatogastroenterology 1998; 45: 2443–6.

34. Gohary O.M., Din K., Tahir H. Formulation of aspirin-magaldrate double-layer tablets: in vitro evaluation and cytoprotective activity in rats. Boll Chim Farm 1996; 135: 421–8.

35. Mach T . In vivo and vitro study of prostaglandins E2 and I2 participation in protective function of antacids on gastric mucosa. Folia Med Cracov 1992; 33: 37–51.

36. Gasbarrini G., Andreone P ., Baraldini M. et al. Protection of the upper gastrointestinal mucosa: the role of antacids. Int J Clin Pharmacol Res 1990;10: 173–8.

37. Konturek S.J., Brzozowski T ., Majka J., et al. Implications of nitric oxide in the action of cytoprotective drugs on gastric mucosa. J Clin Gastroenterol 1993; 17 Suppl 1: S140–5.

38. Muller P ., Dammann H.G., Simon B. Protective effect of two antacids in acute acetylsalicylic acid-induced injuries to the human gastric mucosa. Arzneimittelforschung 1985; 35: 1862–4.

39. Linnoila M., Lehtola J. Absorption, and effect on gastric mucosa, of buffered and non–buffered tablets of acetylsalicylic acid. Int J Clin Pharmacol Biopharm 1977; 15: 61–4.

40. Maev I.V., Samsonov A.A. The use of modern antacids in the treatment of acid disorders of the gastrointestinal tract. Spravochnik Poliklinicheskogo Vracha 2005; 3(5): 43–48. Russian (Маев И.В., Самсонов А.А. Приме-

41. нение современных антацидных средств в терапии кислотозависимых заболеваний желудочно-кишечного тракта. Справочник Поликлинического Врача 2005; 3(5): 43–48).

42. Kukes V .G., Ostroumova O.D. Cardiomagnyl. A new view of acetylsalicylic acid. A Handbook for Physicians. Moscow; 2004. Russian (Кукес В.Г ., Остроумова О.Д. Кардиомагнил. Новый взгляд на ацетилсалициловую кислоту. Пособие для врачей. M.; 2004).

43. Vovk E.I., Naumov A.V., Chudakov S.Yu. An effective and safe antiplatelet therapy in general practice. Vrach Skoroy Pomoshchi 2006; (1): 51–59. Russian (Вовк Е.И., Наумов А.В., Чудаков С.Ю. Эффективная и безопасная антиагрегантная терапия в общемедицинской практике. Врач Скорой Помощи 2006; (1): 51–59).

For citation:

Govorin A.V., Filev A.P. ACETYLSALICYLIC ACID IN THE PREVENTION OF ATHEROTHROMBOTIC EVENTS. Rational Pharmacotherapy in Cardiology. 2012;8(2):237-241. (In Russ.)

Views: 555

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)